Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Billionaire David Shaw’s D. E. Shaw & Co. and AMAG Pharmaceuticals Inc. (AMAG)

Page 1 of 6

D. E. Shaw Co., a fund founded by billionaire quant David Shaw, has disclosed its position in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) in a recent filing with the Securities and Exchange Commission. According to the 13G filing, D. E. Shaw owns 1.73 million shares of AMAG, which represent 5.0% of the company’s outstanding stock. The position is passive by nature.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
D. E. Shaw Co., L.P. 13-3695715 1,729,526 1,735,509 1,735,509 5.0%
David E. Shaw 1,729,526 1,735,509 1,735,509 5.0%

Page 1 of 6 SEC Filing

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

 

AMAG Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.01

(Title of Class of Securities)

 

00163U106

(CUSIP Number)

 

January 4, 2016

(Date of Event Which Requires Filing of this
Statement)

Check the following box to designate the rule pursuant to which
the Schedule is filed:

¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing
information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall
not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or
otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Follow Amag Pharmaceuticals Inc. (NASDAQ:AMAG)
Trade (NASDAQ:AMAG) Now!
Page 1 of 6